Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study.

"The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Carmen Escuriola Ettingshausen: grant/research support [Biotest, CSL Behring, Octapharma, Shire (a Takeda company), Sobi]; honoraria for lectures/advisory boards [Bayer, Biotest, CSL Behring, Grifols, Kedrion, LFB, Novo Nordisk, Octapharma, Pfizer, Roche/Chugai, Shire (a Takeda company), Sobi]; and consultancy [BioMarin, Biotest, CSL Behring, Grifols, Novo Nordisk, Octapharma, Roche/Chugai, Shire (a Takeda company), Sobi]. Cedric Hermans: grant/research support [Bayer, Pfizer, Shire (a Takeda company), Sobi]; honoraria for lectures/advisory boards [Bayer, Biogen, CAF-DCF, CSL Behring, Kedrion, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Shire (a Takeda company), Sobi]; and consultancy [Bayer, Biogen, CAF-DCF, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Shire (a Takeda company), Sobi]. Pål A. Holme: grant/research support [Bayer, Octapharma, Pfizer, Shire (a Takeda company), Sobi]; and honoraria for lectures/advisory boards [Bayer, CSL Behring, Novo Nordisk, Pfizer, Shire (a Takeda company), Sobi]. Ana R. Cid: honoraria for lectures/advisory boards [Novo Nordisk, Roche, Shire (a Takeda company), Sobi]; and consultancy (Roche, Sobi). Kate Khair: grant/research support [Baxalta/Shire (a Takeda company), CSL Behring, Novo Nordisk, Pfizer, Roche, Sobi, uniQure]; honoraria for lectures/advisory boards [Bayer, Novo Nordisk, Pfizer, Roche, Shire (a Takeda company), Sobi]; consultancy [Bayer, Novo Nordisk, Roche, Shire (a Takeda company), Sobi]; support attending meetings and/or travel (Bayer, Novo Nordisk); leadership or fiduciary role in other board, society, committee or advocacy group (Vice President board of Trustees The Haemophilia Society); and stock or stock options (Haemnet Ltd, Medikhair). Johannes Oldenburg: grant/research support [Bayer, Biotest, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Shire (a Takeda company)]; honoraria for lectures/advisory boards [Bayer, Biogen, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Shire (a Takeda company), Sobi]; and consultancy [Bayer, Biogen, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Shire (a Takeda company), Sobi]. Claude Négrier: grant/research support [CSL Behring, Octapharma, Shire (a Takeda company), Sobi]; and consultancy [Bayer, BioMarin, CSL Behring, Freeline, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Shire (a Takeda company), Sobi, Spark]. Jaco Botha: employee of Takeda Pharmaceuticals International AG, and Takeda stock owner. Aurelia Lelli: employee of Takeda Pharmaceuticals International AG, and Takeda stock owner. Jerzy Windyga: grant/research support and honoraria for lectures [Amgen, Alnylam, Baxalta/Shire (a Takeda company), Bayer, CSL Behring, LFB, Novartis, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Siemens, Sobi, Swixx Biopharma]."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The FEIBA GO study was funded by Baxalta Innovations GmbH, a Takeda company, Vienna, Austria."